Periscopic View on COVID 19 Infection: A Review

Waliza Ansar

Assistant Professor, Undergraduate Department of Zoology, Behala College, Upen Banerjee Road, Parnasree, Kolkata-700060, India.

Correspondence E-mail : waliza_ansar@yahoo.co.in.

Abstract

Recently, the world has experienced an unprecedented health risk. The unknown coronavirus (SARS-CoV-2 causing COVID-19) is causing a pandemic infection as announced by World Health Organization. It emerged from Wuhan, China in December 2019 and spread worldwide. The SARS-CoV-2 originated in bats and through yet unknown intermediary animals was transmitted to humans in Wuhan. There have been around 3,935,559 reported cases of coronavirus disease 2019 (COVID-2019) and 271,170 reported deaths to date (08/05/2020). It spreads mainly through the droplet route by inhalation or contact. Incubation period 1-14 d. Asymptomatic or patients with mild symptoms is most common of the cases; case fatality nearly 2-3%). The major symptoms are fever, dry cough, fatigue and muscle pain; less common symptoms reported are runny nose, sore throat, diarrhea, chills and hemoptysis. The SARS-CoV-2 infection is a life-threatening complication of acute respiratory distress syndrome (ARDS); in severe cases with other co-morbidities, which most commonly occurs more often in elderly or immunocompromised individuals with underlying diseases. Severe expression of the infection needs treatment in the intensive care unit with indications of acute lung inflammation, ARDS, sepsis and septic shock. Diagnosis of virus in respiratory secretions is done by special molecular tests. This review presents information about history, etiology, pathogenesis, clinical diagnostics, treatment and prevention of the infection. At present, the effective antiviral drug or vaccine is not yet available and the number of infections/death tolls surging day by day, so updated knowledge of this infection is always needed prevention for fighting the virus.

Keywords: Coronaviruses, COVID-19, SARS-CoV-2, acute respiratory distress syndrome (ARDS), SIRS.

Introduction

From the last months of 2019, alarming news from Wuhan, Hubei Province, China followed by spreading around China about a major outbreak of viral infections with 2019-novel coronavirus (2019-nCoV, named on 12 January, 2020 by World Health Organization, WHO)–infected pneumonia (NCIP)(Huang et al., 2020; Zhu et al.,2020; Li et al., 2020b). The infection gradually spread to other parts of the world, which was caused by a novel β-coronavirus. At present, the disease has spread to more than a dozen countries of European countries, America and Asia and Africa (Phan et al., 2020a; Holshue et al., 2020; Giovanetti et al., 2020). Till 08/05/2020 nearly 3,935,559 reported cases of COVID-19, 271,170 deaths, and so far 1,350,951 people recovered have been reported
India has reported 56,561 confirmed cases of which 16,881 recovered cases till 08.05.20 (https://www.covid19india.org).

On January 30, 2020, WHO declared this outbreak a Public Health Emergency of International Concern (PHEIC) (WHO, 31 January 2020; https://www.who.int/news-room/detail/30-01-2020). It was previously known to be 2019-nCov, now referred as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Study Group (CSG, 11 February, 2020) of the International Committee on Taxonomy of Viruses based on phylogeny, taxonomy and established practice (Gorbalenya et al., 2020); the disease it caused has been named by the WHO as COVID-19 (Coronavirus Disease 2019) (WHO, 11 February 2020; https://www.who.int/dg/speeches/detail/11February2020).

Fortunately till date, children have been infrequently affected with no deaths (https://www.worldometers.info/coronavirus).

This article gives a periscopic view about this new virus. Since information about this virus is rapidly evolving, readers are advised to update themselves regularly. But the future itinerary of this virus is still unknown. The disease started as a ‘pneumonia of unknown etiology’ which was quite related to SARS outbreak in 2002-2003. Presently timely management of 2019-nCoV is the need worldwide.

Most human coronavirus infections are mild, the epidemics of the SARS-CoV in 2002-2003 (Ksiazek et al., 2003) and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, Saudi Arabia (de Groot et al., 2013) have struck more than 10,000 swelling cases in the past two decades. The newly identified coronaviruses causing more novel and severe zoonotic events and it might only be the tip of the iceberg (Huang et al., 2020).

According to WHO, about 80% of COVID-19 infection are asymptomatic or mild, 15% are severe form of infection, rest 5% are critical. The infection mortality rate (the number of reported deaths divided by the number of infection) and the crude mortality ratio (number of reported deaths divided by reported cases) will be 3-4% and 0-1% (less than seasonal influenza) respectively (WHO).

Patients from Wuhan and other provinces in China, Japan, Thailand, South Korea, USA and in other areas showed clusters of fatal pneumonia caused by 2019-nCoV with clinical presentation greatly resembling SARS-CoV. These patients might develop acute respiratory distress syndrome (ARDS), have a high probability of admission to ICU, and might die. Disease severity could be associated with the cytokine storm (Huang et al., 2020).

**History and evolution**

Though coronaviruses were first discovered in the 1930s in domesticated chicken (Avian bronchitis virus) as an acute respiratory infection but human coronaviruses (HCoV; successfully isolation from HCoV strain B814 of patients with common cold) were discovered in the 1962 (Mahase 2020; Estola1970; Kendall et al., 1962), some novel HCoVs(1960s) were described without much characterization (McIntosh et al., 1967; McIntosh, 1974). Subsequently all seven HCoVs(nSARS-CoV, SARS-CoV, MERS-CoV, 229E, OC43, HKU1 and NL63) have a zoonotic origin from bats, birds, rodents, or other domestic animals. The most recent common ancestor of the β-coronavirus existed at 3300 BCE (Woo et al., 2012). Birds and Bats are an ideal natural reservoir for the coronavirus gene pool. NL63 and 229E shared a common ancestor with a bat coronaviruses (ARCoV.2 and GhanaGrp1 Bt CoV) between 1190–1449 CE and 1686–1800 CE respectively (Pfefferle et al., 2009).

The ancestors of SARS-CoV first infected leaf-nose bats (genus Hipposideridae); then subsequently, spread through horseshoe bats, civets, and finally to humans (Cui et al., 2007). The clinical features of 229E (a prototype strain) and OC43 (in the pre-SARS era) were characterized in human volunteers (McIntosh, 1974). HKU1 (in 2005) and NL63 (in 2004) were first isolated from a pneumonia patient and a child with bronchiolitis respectively (van der Hoek et al., 2004; Lau et al., 2006; Zhu et al., 2020). HKU1 and NL63 reported to cause mild respiratory diseases around the world (van der Hoek et al., 2005). 229E OC43, HKU1 and NL63 are community
acquired HCoVs causing severe lower respiratory tract disease only in rare cases in human host also (Wang et al., 2020c).

SARS-CoV does not cause mild infections like its ancestors. SARS-CoV infection turned into a SARS epidemic in 37 countries (case fatality of 9.6%) (Perlman and Netland, 2009). In the past two decades, two severe disease events (mortality rate 11-34%) have been recorded by transmission of animal β-coronaviruses to humans. In 2002–2003, the first such instance occurred in Guangdong province of China when a new β-coronavirus crossed from bat to humans through palm civet cats, affecting 8422 people mostly in China and Hong Kong and caused 916 deaths before being contained (Chan-Yeung and Xu, 2003). In 2012, a decade later, in Saudi Arabia, the MERS-CoV, with bat origin, emerged with intermediate host dromedary camels by affecting 2494 people and 858 deaths. Exported MERS cases with sporadic recurring outbreaks were also reported outside Arabian world since 2012 with186 confirmed cases in 2015 in South Korea. Clinical symptoms ranges from asymptomatic to critical ARDS also (Zumla et al., 2015; Zhou et al., 2017; Yeung et al., 2016; https://www.who.int/emergencies/mers-cov/en/).

Through evolution, the reservoir hosts of these viruses are selected. During the long period of this selection and mutual adaptation, they usually cause very mild (by 229E, HKU1, NL63 and OC43) or non-pathogenic diseases, remain dormant in their native reservoir hosts. However, when this animal virus enters a new host like humans, a new round of adaptation starts with more severe form of the disease (Fung et al., 2020) like the SARS-CoV (Zhong et al., 2003; Drosten, et al., 2003) and the MERS-CoV outbreak (Zaki et al., 2012). These viruses’ remains in the circulation in camels and in December 2019 the SARS-CoV-2 coronaviruses emerged in Wuhan of China and presently spreading worldwide (Zhu et al., 2019).

Epidemiology

The transmission and source(s) of SARS-CoV-2 were elucidating. In SARS-CoV-2 infection, human-to-human transmission occurs mainly within family members, friends and relatives who intimately contacted the infected patients or incubation carriers. People recently travelled to Wuhan or non-residents people who contacted patients from Wuhan got infected (Guan et al., 2020). National Health Commission of China on 14 February 2020 reported that 3.8% of COVID-19 patients were transmission between healthcare workers. Consumption of wild animals or direct contact with intermediate host animals was suspected to be the primary route of SARS-CoV-2 transmission (Guo et al., 2020).

Since 12 December 2019, from Wuhan seafood market, the first epidemic of unknown acute respiratory tract infection broke out. Bat may be the potential reservoir of SARS-CoV-2 (Giovanetti et al., 2020; Paraskevis et al., 2020) as known also bats are the natural reservoir of SARS-CoV-like, MERS-CoV-like viruses, and a wide variety of CoVs (Hampton, 2005; Banerjee et al., 2019; Li et al., 2005). Upon virus genome sequencing, the SARS-CoV-2 showed 96.2% overall genome sequence identity to bat CoV RaTG13 (Zhou et al., 2020) and 79.5% identity to SARS-CoV (Zhou et al., 2020); thus bat CoV and human SARS-CoV-2 might carve up the same ancestor, although bats were not sold in Wuhan seafood market (Wu et al., 2020). Protein sequences alignment and phylogenetic analysis (Liu et al., 2020) revealed similar residues of receptor in various species (Bat, swine, civet), which elucidate possibility of alternative intermediate hosts, like turtles, pangolin and snacks.

Coronavirus family, morphology and structure

Coronavirus is an enveloped virus (60 nm to 140 nm in diameter) with a RNA polycistrionic genome, single stranded positive-sense strand (length 26 to 32 kb) referred for its solar corona (Latin word corona means crown; transmission electron microscopy imaging) like appearance with 9-12 nm-long surface spikes (Wang et al., 2020a). It belongs to the family Coronaviridae and the order Nidovirales (subgenus Sarbecovirus, subfamily Orthocoronavirinae) (Huang et al., 2020; Richman et al., 2016, Zhu et al., 2020). The severe form of this family of HCoVs includes
the recent nCoV/β-coronavirus (COVID-19), SARS-CoV and MERS-CoV with the less severe ones like HKU1, NL63, OC-43 and 229E (229E and NL63 belong to α-coronavirus) (Zhou et al., 2020). The α- and β-CoV are able to infect mammals, but γ- and δ-CoV infect birds (Guo et al., 2020).

There are four major structural proteins [small envelope (E) protein, matrix (M) protein, spike (S) like surface glycoprotein, and nucleocapsid (N) protein] on the envelope encoded by the coronaviral genome. Several other accessory proteins also interfere with the host innate immune response (Cui J et al., 2019). The spike protein on the envelope binds with angiotensin-converting enzyme 2 (ACE2) receptor for fusion with host cell membranes and to enter respiratory mucosa into the host cell (Hampton,2005) (through S1 and S2 distinct functional domain of spike protein) (Kirchdoerfer et al., 2016; Xu et al., 2020; Velavan and Meyer, 2020; Phan et al., 2020a,b).

**Genomic characteristics**

The genome deep sequencing of SARS-CoV-2 was done by clinical samples from several laboratories (Zhy et al., 2020; Zhou, et al., 2020 ; Lu et al., 2020b; Chen et al., 2020c; Chen et al., 2020b; Chan et al., 2020). The SARS-CoV-2 viral genome is around 29.8 kilobase, with a G+C content of 38%. It has six major open reading frames (ORFs) in total common to coronaviruses and some other accessory genes (Zhou et al., 2020; Chan et al., 2020). The genome sequences of viruses from different patients are highly conserved (Zhou et al., 2020; Lu et al., 2020b; Xu et al., 2020), revealing that this human virus evolves recently.

In groundwork report, complete viral genome analysis discloses that the virus shares 88% sequence homology to two bat-derived SARS-like-coronaviruses (Lu et al., 2020b). Besides, phylogenetic analysis and protein sequences alignment (Liu et al., 2020) revealed that analogous residues of receptor were seen in many species, which presented more possibility of intermediate alternative hosts, like pangolin, turtles, and snacks (Guo et al., 2020). SARS-CoV-2 uses ACE2 receptor like the SARS-CoV (Zhou et al., 2020), to infect humans.

The 2019-nCoV mutate faster than DNA viruses (Tang et al., 2020). 2019-nCoV has the inherent attribute of high mutation rate, as an RNA virus. Due to high mutations and recombination rate of this virus, diverse viral strains are evolving with new features. But the presence of genome encoded exonuclease, lower the mutation rate in comparison to other RNA viruses (Zhou et al., 2020; Tang et al., 2020; Sanjuän and Domingo-Calap,2016).

Deep meta-transcriptomic sequencing on Wuhan-Hu-1 coronavirus (WHCV), recently showed 16 predicted non-structural proteins (NSP). WHCV and SARS-CoV exhibits similarity to S-glycoprotein gene and receptor-binding domain (RBD), reported by some phylogenetic and genomic analysis, indicating their capability of direct human transmission. No amino acid substitutions occurred in NSP7, NSP13, envelope, matrix, or accessory proteins (p6 and 8b) at the protein level between WHCV and SARS-CoV , except in NSP2, NSP3, spike protein, underpinning the RBD (Wu et al., 2020). Mutation in NSP2 and NSP3 play a role in differentiation mechanism and infectious capability of SARS-CoV-2 (Angeletti et al., 2020). Thus transmission and host tropism between SARS-CoV-2 and SARS-CoV need to be explored for future therapeutic targets (Zhang et al., 2020a). Report showed that SARS-CoV-2 had been mutated in various patients in China as analyzed from the genotypes of COVID-19. Moreover, the degree of diversification of SARS-CoV-2 is smaller than the mutation of H7N9 avian influenza (Wu et al., 2015). L type (~70%) and S type (~30%) are the two prevalent evolvement types of SARS-CoV-2, as revealed by population genetic analyses of 103 SARS-CoV-2 genomes. The L type strains is evolutionarily more aggressive and contagious posing concern for virologists to closely monitor the virulence and epidemic of 2019-nCoV (Tang et al., 2020).

**Transmission and clinical characteristics**

As an emerging acute respiratory infectious disease, COVID-19 spreads primarily by droplets, direct contact and respiratory secretions (Li et al., 2020) through the
respiratory tract, in a low infective dose (Lee and Hsueh, 2020); fecal swabs and blood in severe cases (Zhang et al., 2020a,b); largely transmitted from symptomatic patients through inhaled or by touching contaminated surface infectious droplets (and fomites) generated during sneezing and coughing. Acquired Infection is then spread by touching the eyes, nose and mouth. The virus is also present in the stool and contamination water supply and consequent aerosol transmission through feco-oral route (Zhu et al., 2020). These infected droplets can deposit on surfaces with a spread of 1–2 m for days in favorable atmospheric conditions. All ages are at risk. It can also transmit from asymptomatic people and before the onset of symptoms (Giovanetti, 2020).

The virion entry interaction between S protein and human ACE2 receptor (hACE2) on lung alveolar epithelial cells may help to understand the viral infection routes and disease manifestations. The present SARS-CoV-2 has the incubation period is 1–14 d and is contagious during the latency period (Jin et al., 2020). It is vastly transmissible in humans, especially in the elderly (> 65 years) and immunocompromised people.

No difference in viral burden between asymptomatic and symptomatic people was noted. Studies showed higher viral loads in the nasal cavity than in the throat (Banerjee et al., 2019). Patients remain infectious as long as the symptoms persist or may extend on clinical recovery also. The virus can be killed in less than a minute by common disinfectants like hydrogen peroxide, sodium hypochlorite, etc. (Li, 2005). As per current information, transplacental transmission from pregnant women to their fetus has not been described (Chen et al., 2020d; Aiping et al., 2020). ACE2, a carboxypeptidase, essentially removes carboxy-terminal of basic or hydrophobic amino acids. ACE2 is normally expressed in human lungs on type-I and type-II lower alveolar epithelial cells. ACE2 more expressed in mouth than tongue. The high affinity of SARS-CoV-2 for cellular receptor present in the upper respiratory tract causes faster transmission (Banerjee et al., 2020). The current data on the COVID-19 showed that it might be initially hosted by bats (Hipposideros larvatus) (Gouilh et al., 2011), and then transmitted to humans through pangolin (Lam et al., 2020) or various wild animals (Lu et al., 2020a; Zhang et al., 2020a,b) sold at the Hunan market but then subsequently it took human-to-human transmission route with mild common cold-like symptoms, but in immunocompromised patients severe lower respiratory tract infection develops (Pene et al., 2000). The virus can co-infect different vertebrates species including humans and affect gastrointestinal, respiratory and CNS infection; with life-threatening ARDS in some critically ill patients (Leung et al., 2003; Xu et al., 2005; Lu et al., 2020a).

The superspreading events in the SARS-CoV transmission in 2002 are thought to be the release of large amounts of virions. The use of immunosuppressive agents and mutation of virus susceptibility genes encoding restriction factors in host antiviral defense might boost viral replication with shedding of large amounts of virus (Stein, 2011). Thus host antiviral immune response facilitates superspreading. SARS-CoV was identified and isolated as the causative agent of SARS (Peiris et al., 2003) with lower respiratory tract infection, cytokine storm and poor outcome in patients.

**Virus replication, infection and pathogenesis**

Cellular entry receptor for SARS-CoV-2 (like SARS-CoV), is the ACE2 found in the humans lower respiratory tract (Zhou et al., 2020; Jia et al., 2005). ACE2 protein is abundantly present on lung alveolar epithelial cells and in enterocytes of small intestine (Hamming et al., 2004). ACE2 regulates both human-to-human and the cross-species transmission (Wan et al., 2020). S-glycoprotein on the surface of coronavirus can attach to the ACE2 on the surface of human cells (Tortorici and Veesler, 2019). Virus-receptor binding affinity is a critical step in SARS-CoV infection. S-glycoprotein includes two subunits, S1 and S2 (Zhang, et al., 2014). S1 determines the cellular tropism and virus-host range through its RBD. S2 causes virus-cell membrane fusion by heptad repeats 1 (HR1) and HR2.
the two tandem domains (Xia et al., 2020; Yu et al., 2020). The viral genome RNA, after the membrane fusion, is released into the cytoplasm. The uncoated RNA translates two polyproteins, pp1a and pp1ab (de Wilde et al., 2018). The pp1a and pp1ab encode non-structural proteins and form the replication-transcription complex (RTC) in double-membrane vesicle (Sawicki and Sawicki, 2005). RTC continuously replicate to form a nested set of subgenomic RNAs (Hussain et al., 2005) to encode structural and accessory proteins. The newly formed genomic RNA, envelope glycoproteins and nucleocapsid proteins assemble to form viral particle buds (Perrier et al., 2019). Lastly, the viruses are released through fusion of virion-containing vesicles with the plasma membrane. Human cells expressing ACE2, but not human APN (Aminopeptidase N) or Dipeptidyl peptidase-4 (DPP4), were more viable for SARS-CoV-2 entry using the ACE2 receptor (Letko et al., 2020). The pathogenesis is controlled by the balancing reaction between the virus and host antiviral defense. The virus and host co-exist peacefully through years of co-evolution in mutual benefit in a balancing environment. The viral pathogenesis of SARS-CoV-2 is revealing each day, but idea of host antiviral immunity can be elucidated from other human pathogenic virus families (Fung et al., 2020).

Symptoms, complications and clinical presentation

Common symptoms at onset of illness were fever, dry cough, sore throat, shortness of breath (dyspnoea), and fatigue or myalgia, lymphopenia; less common symptoms were headache, sputum production, haemoptysis and diarrhea, vomiting. However, gastrointestinal and upper respiratory symptoms were rare. Thus the viral tropism of SARS-CoV-2 is different from SARS-CoV (Lee et al., 2003), influenza (Wang et al., 2016) and with MERS-CoV (Assiri et al., 2013).

All patients had pneumonia with abnormal findings on chest CT imaging (Huang et al., 2020) reflecting that the chest was ground-glass opacity and bilateral patchy shadowing(Guan et al., 2020). Sometimes a rounded morphology with a peripheral lung distribution was analyzed from patients (Chung et al., 2020). However, a part of confirmed patients showed normal CT images. The diagnostic sensitivity lies in virus RNA detections and evaluation of clinical symptoms.

This disease was caused by virus-stimulated pneumonia demonstrated by clinicians according to clinical signs and symptoms like increased body temperature, lymphocytopenia and leucopenia (or WBC in normal range), new pulmonary infiltrates visible on chest radiography and no apparent improvement after antibiotics treatment for three days. Most of the early cases appeared by contact history with the Wuhan seafood market; thereafter, the disease transmitted by human-to-human contact (Zhou et al., 2020).

The most vulnerable cluster in corona pandemic is elderly, hypertensive, immune compromised (diabetes, cardiovascular disease, chronic obstructive pulmonary disease) individuals who may rapidly develop septic shock, ARDS, metabolic acidosis and coagulation dysfunction, multiple organ failure, even leading to the death (Huang et al., 2020).

The malnourished, cancer patients as well as pregnant women were also susceptible. Predictable pattern of clinical course is somehow utilizable. Flu-like symptom like fever, dry cough, headache, fatigue and myalgia (with back pain), nausea, abdominal discomfort, loss of smell, anorexia with little diarrhea persist on around day 5. Worsening symptoms at this period includes shortness of breath due to bilateral viral pneumonia causing damage to lung parenchyma (as observed by transverse chest computerized-tomography images) and even death. On day 10, cytokine storm triggers, consequently with ARDS and multi-organ failure. In moderate to severe cases patients' usually hypoxic stage present without dyspnea (Zhou et al., 2020).

China reported 15% cardiac cases with serious final outcome. In major of the reported chest X-rays, ground glass opacities or bilateral interstitial pneumonia are seen, but chest auscultations are of no help. Chest X-ray findings does not correlate well mostly with the hypoxia. Reported blood tests showed, in most cases, low WBC count ,low platelet count, elevated CRP, CPK, LDH, D-dimer, ALK -
phos/AST-ALT and ferritin levels whereas procalcitonin concentration in normal range. If the ratio of absolute neutrophil count to absolute lymphocyte count is greater than 3.5, then it may predict poor outcome. Cytokine storm is reflected by high level of IL-6, IL-10, IL-2, IL-7, GSCF, IP10, MCP1, MIP1A, and TNFα (Mehta et al., 2020; Huang et al., 2020). Complications related to disease severity includes ARDS, arrhythmia, RNAaemia, shock, acute kidney injury, liver dysfunction acute cardiac injury and secondary infection (Huang et al., 2020; Wang et al. 2020a). The aged male with ARDS and comorbidities showed a higher death risk due to their weak immune system (Wang et al. 2020a)

**Diagnosis, precaution, prevention**

The viral research institution in China has conducted the preliminary identification of the SARS-CoV-2 by observing its morphology in electron microscopy using the classical Koch’s postulates (Lu et al., 2020a). The clinical diagnosis method of COVID-19 disease is by nucleic acid detection in the throat swab and nasal / other respiratory tract sampling (s) or by real-time PCR and further confirmed by next-generation sequencing [Guo et al., 2020]. Initial plasma concentration of IL1B, IL1RA, IL7, IL8, IL9, IL10, GCSF, basic FGF, GMCSF, IFNy, IP10, MCP1, MIP1A, MIP1B, TNFα, PDGF, and VEGF were higher in both ICU and non-ICU patients than healthy subjects. Plasma levels of ILS, IL12p70, IL15, RANTES and Eotaxin, were comparable with healthy adults (Huang et al., 2020).

Disease onset may show speedy advancement to organ dysfunction (such as shock, acute cardiac injury, etc) and in severe cases even death (Wang et al., 2020a; Chen et al., 2020c). Patients during the period might show normal or lower WBC counts (leucopenia; less than 4 × 10^9/L), thrombocytopenia or lymphopenia (lymphocyte count <1.0 × 10^9/L), increased prothrombin time, increased C-reactive protein level with extended activated thromboplastin time. Procalcitonin within normal range of patients on admission (<0.1 ng/mL) (Huang et al., 2020). Procalcitonin may only increase in case of bacterial coinfection.

Initial investigations included a complete hemogram, coagulation contour, and serum biochemical investigation (like liver and renal function, lactate dehydrogenase, creatine kinase, and electrolytes). Nasal and pharyngeal swabs, sputum, bronchoalveolar lavage fluid, or bronchial aspirates were tested for common viruses, like adenovirus, influenza, avian influenza, parainfluenza virus, respiratory syncytial virus, MERS-CoV and SARS-CoV. Routine bacterial and fungal investigations were also performed.

**Treatment**

There are no specific medicines or vaccines for COVID-19 at present. Clinical experiences and few clinical trials in affected pandemic areas form the descriptive reports of treatment procedures. The viral genome sequencing of SARS-CoV-2 facilitates epidemiologic tracing, rapid diagnostic evaluation, and management of therapeutic and preventive strategies. Inavailability of effective antiviral therapy, current treatments against COVID-19 mainly highlighted on respiratory and symptomatic support according to the Diagnosis and treatment Protocol(http://www.gov.cn/zhengce/zhengceku/2020). Though all patients received oxygen therapy by WHO recommendations, patients with refractory hypoxemia received extracorporeal membrane oxygenation (ECMO) (WHO, https://www.who.int/publicationsdetail). In some critical cases, immunoglobulin G and convalescent plasma as rescue treatment were given (Chen et al., 2020a). Neuraminidase inhibitors (like oseltamivir, peramivir etc) used for influenza virus, were not recommended for COVID-19(Wang et al., 2020a, b; Li et al., 2020a).

There are no clinical trial data supporting any prophylactic therapy. Though above 300 active clinical trials are ongoing, no randomized clinical trials (RCTs) with outcome of potential therapy in suspected or confirmed COVID-19 patients is noted (Sanders et al., 2020). Chloroquine blocks SARS-CoV-2 in vitro at a half-maximal effective concentration (EC50) whereas hydroxychloroquine has a lower EC50 in vitro (Yao et al., 2020). Ongoing Clinical trials of remdesivir (formally known as GS-
5734) to evaluate the antiviral activity and safety in patients with mild/ moderate/severe COVID-19 (NCT04292899, NCT04292730, NCT04257656, NCT04252664, NCT04280705) (Sanders et al., 2020) but it is not currently FDA-approved. Till date, favipiravir and corticosteroids (should not be used unless otherwise indicated) has not been reported or may be used in limited regime for COVID-19. Tocilizumab (FDA-approved), a monoclonal antibody IL-6 receptor antagonist, with RCTs alone or in combination in COVID-19 patients are underway in China (NCT04310228, ChiCTR200002976) (https://www.china law translate.com/wp-content/uploads/2020/03/Who-translation.pdf). Hyperimmune immunoglobulins or convalescent plasma is another potential adjunctive therapy for COVID-19 (Chen et al., 2020a). The WHO clinical management guidance (as of March 13, 2020) recommended no specific anti-COVID-19 treatment for patients for confirmed COVID-19 patients (WHO March 13), early recognition, treatment of secondary bacterial infections or sepsis and emphasized on supportive care depending on severity of disease or evidence-based ventilator supervision for ARDS (Sanders et al., 2020).

Conclusion

Two epicenters of the pandemic novel coronavirus Covid-19 created were at first the Hubei Province in People's Republic of China and currently in Europe. SARS-CoV-2 is more infective and pathogenic than its other family members like SARS-CoV and MERS-CoV. The alarming wide spread of the disease in different countries, the increasing number of reported cases raises a grave concerns about the future projectile of infection of this virus. It is of utmost importance to understand the pathogenesis, molecular mechanism of transmission, replication and viral entry and future treatment directive of this viral strain.

The outbreak of COVID-19 spread across China fast and has outbreak to 227 countries outside of China as of 8 May 2020 (COVID-19 dashboard, CSSE, 08.05.20). Scientists have characterized the novel coronavirus and made progress for future therapies and vaccines for the virus. We have abridged the current knowledge of SARS-CoV-2. The ongoing supporting treatments and potent antiviral drugs, includes lopinavir/ritonavir, chloroquine, or and remdesivir and others should be supported with definite clinical trials. The provides the basis of potential research for developing targeted treatments. The evolutionary ancestries from the original host, the cross-species or human-human transmission need to be projected.

Acknowledgments

The authors would like to thank the Behala College, under University of Calcutta, India for all infrastructural help and support about this review.

Conflicts of Interest

The authors declare that the research review was conducted in the absence of any commercial or economic associations that could be construed as a potential conflict of interest.

References

Aiping, W., Yousong, P., Baoying, H., Xiao, D., Xianyue, W., Peihua, N., Jing, M., Zhaozhong, Z., Zheng, Z., Jianguan, W., Jie, S., Lijun, Q., Zanxian, X., Wenjie, Genhong, C., Taijiao, J. (2020). Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host & Microbe, 27(3),325–328. doi: 10.1016/j.chom.2020.02.001.

Angeletti, S., Benvenuto, D., Bianchi, M., Giovanetti, M., Pascarella, S., Ciccozzi M. (2020). COVID-2019: the role of the nsp2 and nsp3 in its pathogenesis. J Med Virol, 92(6),584-588. doi: 10.1002/jmv.25719. Epub 2020 Feb 28.

Assiri, A., Al-Tawfiq, J.A., Al-Rabeeah, A.A., Al-Rabiah, F.A., Al-Hajjar, S., Al-Barrak, A., Fiemban, H., Al-Nassir, W.N., Balkhy, H.H., Al-Hakeem, R.F., Makhdoum, H.Q., Zumla, A., Memish, Z.A. (2013). Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis, 13(9),752-61. doi: 10.1016/S1473-3099(13)70204-4. Epub 2013 Jul 26.
Banerjee, A., Kulcsar, K., Misra, V., Frieman, M., Mossman, K. (2019). Bats and Coronaviruses. *Viruses*, 9;11(1), pii: E41. doi: 10.3390/v11010041.

Banerjee, S., Dhar, S., Bhattacharjee, S., Bhattacharjee, P. (2020). Decoding the lethal effect of SARS-CoV-2 (novel coronavirus) strains from global perspective: molecular pathogenesis and evolutionary divergence. *bioRxiv*, preprint doi: https://doi.org/10.1101/2020.04.06.027854.

Chan, JF., Yuan, S., Kok, KH., To, KK., Chu, H., Yang, J., Xing, F., Liu, J., Yip, CC., Poon, RW., Tsio, HW., Lo, SK., Chan, KH., Poon, VK., Chan, WM., Ip, JD., Cai., JP., Cheng, VC., Chen, H., Hui, CK., Yuen, KY. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet*, 15;395(10223), 514-523. doi: 10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24.

Chan-Yeung, M., Xu, RH. (2003). SARS: epidemiology. *Respirology*, 8,59-14. doi: 10.1046/j.1440-1843.2003.00518.x.

Chen, L., Xiong, J., Bao, L., Shi, Y. (2020). Convalescent plasma as a potential therapy for COVID-19. *Lancet Infect Dis*, 20(4),398-400. doi:10.1016/S1473-3099(20)30141-9.

Chen, L., Liu, W., Zhang, Q., Xu, K., Ye, G., Wu, W., Sun, Z., Liu, F., Wu, K., Zhong, B., Mei, Y., Zhang, W., Chen, Y., Li, Y., Shi, M., Lan, K., Liu, Y. (2020). RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak. *Emerg Microbes Infect*, 5(9),313-319. doi: 10.1080/22221751.2020.1725399. eCollection 2020.

Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., Xia, J., Yu, T., Zhang, X., Zhang, L. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*, 15;395(10223), 507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.

Chen, Y., Peng, H., Wang, L., Zhao, Y., Zeng, L., Gao, H., Liu, Y. (2020). Infants Born to Mothers With a New Coronavirus (COVID-19). *Front Pediatr*, 16,8,104. doi: 10.3389/fped.2020.00104. eCollection 2020.

Chung, M., Bernheim, A., Mei, X., Zhang, N., Huang, M., Zeng, X., Cui, J., Xu, W., Yang, Y., Fayad, Z.A., Jacobi, A., Li, K., Li, S., Shan, H. (2020). CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). *Radiology*, 295(1),202-207. doi: 10.1148/radiol.2020200230. Epub 2020 Feb 4.

COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). *ArcGIS*. Johns Hopkins University. Retrieved 8 May 2020.

Cui, J., Li, F., Shi, Z.L. (2019). Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol*, 17(3),181–192. doi: 10.1038/s41579-018-0118-9.

Cui, J., Han, N., Streicker, D., Li, G., Tang, X., Shi, Z., Hu, Z., Zhao, G., Fontanet, A., Guan, Y., Wang, L., Jones, G., Field, H.E., Daszak, P., Zhang, S. (2007). Evolutionary relationships between bat coronaviruses and their hosts. *Emerg Infect Dis*, 13(10),1526-32. doi: 10.3201/eid1310.070448.

de Groot, RJ., Baker, SC, Baric, RS., Brown, CS., Drosten, C., Enjuanes, L., Fouchier RA, Galiano, M., Gorbalenya, AE., Memish, ZA., Perlman, S., Poon, LL, Snijder, E.J., Stephens, GM., Woo, PC, Zaki, AM., Zambon, M., Ziebuhr, J. (2013). Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. *J Virol*, 87(14),7790-2. doi: 10.1128/JVI.01244-13. Epub 2013 May 15.

de Wilde, AH., Snijder, E.J., Kikker, M., van Hemert, MJ. (2018). Host Factors in Coronavirus Replication. *Curr Top Microbiol Immunol*, 419,1-42. doi: 10.1007/82_2017_25.

Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R.A., Berger, A., Bürghiére, A.M., Cinatli, J., Eickmann, M., Escriou, N., Grywna, K., Kramme, S., Manuguerra, J.C., Müller, S., Rickerts, V., Stürmer, M., Vieth, S., Klken, HD., Osterhaus, AD., Schmitz, H., Doerr, HW. (2003). Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med*, 15;348(20),1967-76. Epub 2003 Apr 10.

Estola, T. (1970). Coronaviruses, a new group of animal RNA viruses. *Avian Dis*, 14(2),330-6.

Fung, SY., Yuen, KS., Ye, ZW., Chan, CP., Jin, DY. (2020). A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. * Emerg Microbes Infect*, 14(9),558-570. doi: 10.1080/22221751.1736644. eCollection 2020.
Giovannetti, M., Benvenuto, D., Angeletti, S., Ciccozzi, M. (2020). The first two cases of 2019-nCoV in Italy: Where they come from? *J Med Virol*, 92(5), 518-521. doi: 10.1002/jmv.25699. Epub 2020 Feb 12.

Gorbatenya, AE., Baker, SC., Baric, RS., de Groot, RJ., Drosten, Christian., Gulyaeva, AA., Haagmans, BL., Lauber, Chris., Leontovich, A M., Neuman, BW., Penzar, Dmitriy., Perlman, Stanley., Poon, LLM., Samborskiy, D., Sidorov, IA., Solà, I., Ziebuhr, J. (2020). Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group. *bioRxiv* preprint first posted online February 11., 2020:2020.2002.07.937862. doi:10.1101/2020.02.07.937862.

Gouilh, MA., Puechmaillle, SJ., Gonzalez, JP., Teeling, E., Kittayapong, P., Manuguerra, JC. (2011). SARS-Coronavirus-ancestor’s footprints in South-East Asian bat colonies and the refuge theory. *Infect Genet Evol*, 11(7), 1690–1702. doi: 10.1016/j.meegid.2011.06.021. Epub 2011 Jul 8.

Guan, WJ., Ni, ZY., Hu, Y., Liang, WH., Ou, CY., He, JX., Liu, L., Shan, H., Lei, CL., Hui, DSC., Du, B., Li, LJ., Zeng, G., Yuen, KY., Chen, RC., Tang, CL., Wang, T., Chen, PY., Xiang, J., Li, SY., Wang, JL., Liang, ZJ., Peng, YX., Wei, L., Liu, Y., Hu, YH., Peng, P., Wang, JM., Liu, JY., Chen, Z., Li, G., Zheng, ZJ., Ou, SQ., Luo, J., Ye, CJ., Zhu, S.Y., Zhong, NS., China Medical Treatment Expert Group for Covid-19. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*, 382(18),1708-1720. doi: 10.1056/NEJMoal200232. Epub 2020 Feb 28.

Guo, YR., Cao, QD., Hong, ZS., Tan, YY., Chen, SD., Jin, HJ., Tan, KS., Wang, DY., Yan, Y. (2020). The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak: an update on the status. *Mil Med Res*, 7(1),11. doi: 10.1186/s40779-020-00240-0.

Hamming, I., Timens, W., Bulthuis, ML., Lely, AT., Navis, G., van Goor, H. (2004). Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol*, 203(2), 631-7.

Hampton, T. (2005). Bats may be SARS reservoir. *JAMA*, 9:294(18), 2291.

Holshue, ML., DeBolt, C., Lindquist, S., Lofy, KH., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., Diaz, G., Cohn, A., Fox, L., Patel, A., Gerber, SI., Kim, L., Tong, S., Lu, X., Lindstrom, S., Pallansch, MA., Weldon, WC., Biggs, HM., Uyeki, TM., Pil基, SK., Washington State 2019-nCoV Case Investigation Team. (2020). First Case of 2019 Novel Coronavirus in the United States. *N Engl J Med*, 382(10), 929-936. doi: 10.1056/NEJMoal2001119. Epub 2020 Jan 31.

https://www.covid19india.org/?fbclid=IwAR3PZyu4v9G0vwD0XmqtACAXwzPJEGiDqcv0BcuTumbVuOf9K3WvZLwQDU

https://www.who.int/emergencies/diseases/novel-coronavirus-2019

https://www.worldometers.info/coronavirus

https://www.worldometers.info/coronavirus/?fbclid=IwAR0iC4UYEctYHNMsMKG9fRbNRE8Vz5kTdYDqefYk1MuH_UvBtPnV9ScneQ

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, X., Xie, Y., Yin, W., Li, H., Liu, M., Xiao, Y., Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J., Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*, 15:395(10223), 497-502. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.

Hussain, S., Pan, J., Chen, Y., Yang, Y., Xu, J., Peng, Y., Wu, Y., Li, Z., Zhu, Y., Tien, P., Guo, D. (2005). Identification of novel subgenomic RNAs and noncanonical transcription initiation signals of severe acute respiratory syndrome coronavirus. *J Virol*, 79(9), 5288-95. *Immunol*. 2020. https://doi.org/10.1083/ji.s41423-020-0374-2.

Jia, HP., Lookm DC., Shi, L., Hickey, M., Pewe, L., Netland, J., Farzan, M., Wohlford-Lenane, C., Perlman, S., McCray, PB Jr. (2005). ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. *J Virol*, 79(23), 14614-21.

Jin, YH., Cai, L., Cheng, ZS., Cheng, H., Deng, T., Fan, YP., Fang, C., Huang, D., Huang, LQ., Huang, Q., Han, Y., Hu, B., Hu, F., Li, BH., Li, YR., Liang, K., Lin, LK., Luo, LS., Ma, J., Ma, LL., Peng, ZY., Pan, YB., Pan, ZY., Ren, QG., Sun, HM., Wang, Y., Wang, YY., Weng, H., Wei, CJ., Wu, DF., Xia, J., Xiong, Y., Xu, HB., Yao, XM., Yuan, YF., Ye, TS., Zhang, XC., Zhang, YY., Zhang, YG., Zhang, HM., Zhao, Y., Zhao, MJ., Zi, H., Zeng, XT., Wang, YY., Wang, XH., for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). (2020).
A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res, 6(7):1.4. doi: 10.1186/s40779-020-0233-6.

Kendall, EJ, Bynoe, ML, Tyrrell, DA. (1962). Virus isolations from common colds occurring in a residential school. Br Med J, 14:2(5297):82-6.

Kirchdoerfer, RN, Cottrell, CA, Wang, N., Pallesen, J., Yassine, HM, Turner, HL, Corbett, KS, Graham, BS, McLellan, JS, Ward, AB. (2016). Pre-fusion structure of a human coronavirus spike protein. Nature, 3:531(7602):118-21. doi: 10.1038/nature16849.

Ksiazek, TG, Erdman, D, Goldsmith, CS, Zaki, SR, Peret, T, Emery, S, Tong, S, Urbani, C, Comer, JA, Lim, W, Rollin, PE, Dowell, SF, Ling, AE, Humphrey, CD, Shieh, WJ, Guan, J, Paddock, CD, Rota, P, Fields, B, DeRisi, J, Yang, JY, Cox, N, Hughes, JM, LeDuc, JW, Bellini, WJ, Anderson, LJ. SARS Working Group. (2003). A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med, 15;348(20):1953-66. Epub 2003 Apr 10.

Lam, TT, Shum, MH, Zhu, HC, Tong, YG, Ni, XB, Liao, YS, Wei, W, Cheung, LY, Li, WJ, Li, LF, Leung, GM, Holmes, EC, Hu, YL, Guan, Y. (2020). Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature, 1583(7815):282-285. doi: 10.1038/s41586-020-2169-0.

Lau, SK, Woo, PC, Yip, CC, Tse, H, Tsoi, HW, Cheng, VC, Lee, P, Tang, BS, Cheung, CH, Lee, RA, So, LY, Lau, YL, Chan, KH, Yuen, KY. (2006). Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol. 44(6):2063-71.

Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, GM, Ahuja, A., Yung, MY, Leung, CB., To, KF., Lui, SF., Szeto, CC., Chung, S., Sung, JJ. (2003). A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med, 15;348(20):1986-94. Epub 2003 Apr 7.

Lee, PI, Hseuh, PR. (2020). Emerging threats from zoonotic coronaviruses from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect, 4: pii: S1684-1182(20)30011-6. doi: 10.1016/j.jmii.2020.02.001.

Letko, M., Marzi, A., Munster, V. (2020). Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol, 5(4):562-569. doi: 10.1038/s41564-020-0688-y. Epub 2020 Feb 24.

Leung, WK, To, KF, Chan, PK, Chan, HL, Wu, AK, Lee, N, Yuen, KY, Sung, JJ. (2003). Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology, 125(4):1011-7.

Li, H., Wang, YM, Xu, JY, Cao, B. (2020). Potential antiviral therapeutics for 2019 Novel Coronavirus. Zhonghua Jie He He Hu Xi Za Zhi, 12;43(3):170-172. doi: 10.3760/cma.j.issn.1001-0939.2020.03.004.

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, KSM, Lau, EHY, Wong, JY., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J., Liu, M., Tu, W., Chen, C., Jin, L., Yang, R., Wang, Q., Zhou, S., Wang, R., Liu, H., Luo, Y., Liu, Y., Shao, G., Li, H., Tao, Z., Yang, Y., Deng, Z., Liu, B., Ma, Z., Zhang, Y., Shi, G., Lam, TTY, Wu, JT, Gao, GF, Cowling, BJ., Yang, B., Leung, GM, Feng, Z. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med, 26;382(13):1199-1207. doi: 10.1056/NEJMoA2001316. Epub 2020 Jan 29.

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, KSM, Lau, EHY, Wong, JY., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J., Liu, M., Tu, W., Chen, C., Jin, L., Yang, R., Wang, Q., Zhou, S., Wang, R., Liu, H., Luo, Y., Liu, Y., Shao, G., Li, H., Tao, Z., Yang, Y., Deng, Z., Liu, B., Ma, Z., Zhang, Y., Shi, G., Lam, TTY, Wu, JT, Gao, GF, Cowling, BJ, Yang, B., Leung, GM, Feng, Z. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med, 26;382(13):1199-1207. doi: 10.1056/NEJMoA2001316. Epub 2020 Jan 29.

Li, W., Shi, Z., Yu, M., Ren, W., Smith, C., Epstein, JH, Wang, H, Cramer, G., Hu, Z., Zhang, H., Zhang, J, McEachern, J, Field, H, Daszak, P, Eaton, BT, Zhang, S, Wang, LF. (2005). Bats are natural reservoirs of SARS-like coronaviruses. Science, 28;310(5748):676-9. Epub 2005 Sep 29.

Liu, Z., Xiao, X., Wei, X., Li, J., Yang, J., Tan, H., Zhu, J., Zhang, Q., Wu, J., Liu, L. (2020). Composition and divergence of coronavirus spike protein and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol, 92(6):595-601. doi: 10.1002/jmv.25726. Epub 2020 Mar 11.

Lu, H., Stratton, OW, Tang, YW. (2020). Outbreak of pneumonia of unknown etiology in Wuh
an, China: The mystery and the miracle. J Med Virol, 92(4),401-402. doi: 10.1002/jmv.25678. Epub 2020 Feb 12.

Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., Chen, J., Meng, Y., Wang, J., Lin, Y., Yuan, J., Xie, Z., Ma, J., Liu, WJ, Wang, D., Xu, W., Holmes, EC, Gao, GF, Wu, G., Chen, W., Shi, W., Tan, W. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 22;395(10224),565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.

Mahase, E. (2020). Covid-19: Coronavirus was first described in The BMJ in 1 965. BMJ, 16;369, m1547. doi: 10.1136/bmj.m1547.

McIntosh, K. (1974). Coronavirus: a comparative review. Curr Top Microbiol Immunol, 63,85–129.

McIntosh, K., Dees, JH., Becker, WB., Kapikian, AZ., Chanock, RM. (1967). Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci USA, 1967;57,933–940.

Mehta, P., McAuleym DF., Brown, M., Sanchez, E., Tattersall, RS., Manson, JJ., HLH Across Speciality Collaboration, UK., (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 28;395(10229),1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.

Middle East Respiratory Syndrome Coronavirus. Available at: https://www.who.int/emergencies/mers-cov/en/. Accessed 9 May 2020.

National Health Commission and State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia. Accessed May 18, 2020. https://www.chinalawtranslate.com/wp-content/uploads/2020/03/Who-translation.pdf

National Health Commission of the People’s Republic of China. Diagnosis and Treatment of Pneumonia Caused by 2019-nCoV (version 6). 2020. http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm. Accessed 9 May 2020.

Paraskesiv, D., Kostaki, EG., Magiorkinis, G., Panayiotakopoulos, G., Sourvinos, G., Tsiodras, S. (2020). Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol, 79:104212. doi: 10.1016/j.meegid.2020.104212. Epub 2020 Jan 29.

Peiris, JS., Lai, ST., Poon, LL., Guan, Y., Yam, LY., Lim, W., Nicholls, J., Lee, WK., Yam, WW., Cheung, MT., Cheng, VC., Chan, KH., Tsang, DN., Yung, RW., Ng, WK., Yuen, KY., SARS study group. (2003). Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet, 19;361(9366),1319-25.

Pene, F., Merlat, A., Vabret, A., Rozenberg, F., Buzyn, A., Dreyfus, F., Cariou, A., Freymuth, F., Lebon, P. (2003). Coronavirus-related pneumonia in immunocompromised patients. Clin Infect Dis, 1;37(7),929-32. Epub 2003 Sep 8.

Perlman, S., Netland, J. (2009). Coronavirus post-SARS: update on replication and pathogenesis. Nat Rev Microbiol, 7(6),439-50. doi: 10.1038/nrmicro2147.

Perrier, A., Bonnin, A., Desmarets, L., Danneels, A., Goffard, A., Rouillé, Y., Dubuisson, J., Belouzard, S. (2019). The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal. J Biol Chem, 27,294(39),14406-14421. doi: 10.1074/jbc.RA119.008964. Epub 2019 Aug 9.

Pfefferle, S., Oppong, S., Drexler, JF., Gloza-Rausch, F., Ipsen, A., Seebens, A., Müller, MA., Annan, A., Vallo, P., Adu-Sarkodie, Y., Kruppa, TF., Drost, C. (2009). Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana. Emerg Infect Dis, 15(9),1377-84. doi: 10.3201/eid1509.090224.

Phan, LT., Nguyen, TV., Luong, QC., Nguyen, TV., Nguyen, HT., Le, HQ., Nguyen, TT., Cao, TM., Pham, QD. (2020). Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. N Engl J Med, 27,382(9),872-874. doi: 10.1056/NEJMc2001272. Epub 2020 Jan 28.

Phan, T. (2020). Genetic diversity and evolution of SARS-CoV-2. Infect Genet Evol, 81,104260. doi: 10.1016/j.meegid.2020.104260. Epub 2020 Feb 21.

Richman, DD., Whitley, RJ., Hayden, FG. (2016). Clinical virology, 4th edn. ASM Press, Washington.

Sanders, JM., Monogue, ML., Jodlowski, TZ., Cutrell, JB. (2020). Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19); A Review. JAMA, 13. doi: 10.1001/jama.2020.6019.
Sanjuán, R., Domingo-Calap, P. (2016). Mechanisms of viral mutation. *Cell Mol Life Sci*, 73(23), 4433–4448. https://doi.org/10.1007/s00018-016-2299-6.

Sawicki, SG., Sawicki, DL. (2005). Coronavirus transcription: a perspective. *Curr Top Microbiol Immunol*, 287,31-55.

Stein, RA. (2011). Super-spreaders in infectious diseases. *Int J Infect Dis*, 15(8), e510-3. doi: 10.1016/j.ijid.2010.06.020. Epub 2011 Jul 6.

Tang, X., Wu, C., Li, X., Song, Y., Yao, X., Wu, X., Duan, Y., Zhang, H., Wang, Y., Qian, Z., Cui, J., Lu, J. (2020). On the origin and continuing evolution of SARS-CoV-2. *Nat Sci Rev*, 10.1093/nsr/nwaa036.

Tortorici, MA., Veesler, D. (2019). Structural insights into coronavirus entry. *Adv Virus Res*, 105, 93-116. doi: 10.1016/bs.aivir.2019.08.002. Epub 2019 Aug 22.

van der Hoek, L., Pyrc, K., Jeibbink, MF., Vermeulen-Oost, W., Berkhou, RJ., Wolthers, KC., Wertheim-van Dillen, PM., Kaandorp, J., Spaargaren, J., Berkhou, B. (2004). Identification of a new human coronavirus. *Nat Med*, 10(4), 368-73. Epub 2004 Mar 21.

van der Hoek, L., Sure, K., Ihorst, G., Stang, A., Pyrc, K., Jeibbink, MF., Petersen, G., Forster, J., Berkhou, B., Uberla, K. (2005). Croup is associated with the novel coronavirus NL63. *PLos Med*, 2(8), e240. Epub 2005 Aug 23.

Velavan, TP., Meyer, CG. (2020). The COVID-19 epidemic. *Trop Med Int Health*, 25(3), 278-280. doi: 10.1111/tmi.13833. Epub 2020 Feb 16.

Wan, Y., Shang, J., Graham, R., Baric, RS., Li, F. (2020). Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J Virol*, 17:94(7), e00127-20. doi: 10.1128/JVI.00127-20. Print 2020 Mar 17.

Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*, 7:323(11), 1061-1069. doi: 10.1001/jama.2020.1585.

Wang, H., Xiao, X., Lu, J., Chen, Z., Li, K., Liu, H., Luo, L., Wang, M., Yang, Z. (2016). Factors associated with clinical outcome in 25 patients with avian influenza A (H7N9) infection in Guangzhou, China. *BMC Infect Dis*, 3;16(1),534.

Wang, J., Qi, H., Bao, L., Li, F., Shi, Y., National Clinical Research Center for Child Health and Disorders and Pediatric Committee of Medical Association of Chinese People's Liberation Army. (2020). A contingency plan for the management of the 2019 novel coronavirus outbreak in neonatal intensive care units. *Lancet Child Adolesc Health*, 4(4),258-259. doi: 10.1016/S2352-4642(20)30040-7. Epub 2020 Feb 7.

Wang, Y., Li, X., Liu, W., Gan, M., Zhang, L., Wang, J., Zhang, Z., Zhu, A., Li, F., Sun, J., Zhang, G., Zhuang, Z., Luo, J., Chen, D., Qiu, S., Zhang, L., Xu, D., Mok, CKP., Zhang, F., Zhao, J., Zhou, R., Zhao, J. (2020). Discovery of a subgenotype of human coronavirus NL63 associated with severe lower respiratory tract infection in China. *Emerg Microbes Infect*, 29;9(1),246-255. doi: 10.1080/22221751.2020.1717999. eCollection 2020.

Wei, Q., Wang, Y., Ma, J., Han, J., Jiang, M., Zhao, Li., Ye, Fei., Song, J., Liu, B., Wu, L., Tan, W., Wu, G., Gao, GF., Liu, J. (2020). Description of the first strain of 2019-nCoV, C-Tan-nCoV Wuhan Strain — National Pathogen Resource Center, China, 2020. *China CDC Weekly*, 2(6),81-82.at http://weekly.chinacdc.cn/en/article/id/e3a460f1-661b-4180-b562-eccd8e9502082.

WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. https://www.who.int/publications/detail/clinical-management-of-severe-acute-respiratory-infection-when-novelcoronavirus-(ncov)-infection-is-suspected. Accessed 9 May 2020.

Woo, PC., Lau, SK., Lam, CS., Lau, CC., Tsang, AK., Lau, JH., Bai, R., Teng, JL., Tsang, CC., Wang, M., Zheng, BJ., Chan, KH., Yuen, KY. (2012). Discovery of seven novel Mammalian and avian coronaviruses in the genus delta coronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. *J Virol*, 86(7),3995-4008. doi: 10.1128/JVI.006540-11. Epub 2012 Jan 25.

World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected. Updated March 13, 2020. Accessed May 09, 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-
respiratory-infection when novel coronavirus (ncov)-infection is suspected

World Health Organization. (2005). Statement on the second meeting of the International Health Regulations Emergency Committee regarding the outbreak of novel coronavirus (2019-ncov). 2020. at https://www.who.int/news-room/detail/2020-05-30-statement-on-the-second-conference-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov). Published January 31, 2020.

World Health Organization. (2020). WHO Director-General’s remarks at the media briefing on 2019-ncov on 11 February 2020. at https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. Published February 11, 2020.

Wu, D., Zou, S., Bai, T., Li, J., Zhao, X., Yang, L., Liu, H., Li, X., Yang, X., Xin, L., Xu, S., Zou, X., Li, X., Wang, A., Guo, J., Sun, B., Huang, W., Zhang, Y., Li, X., Gao, R., Shen, B., Chen, T., Dong, J., Wei, H., Wang, S., Li, Q., Li, D., Wu, G., Feng, Z., Gao, GF., Wang, Y., Wang, D., Fan, M., Shu, Y. (2015). Poultry farms as a source of avian influenza A (H7N9) virus reassortment and human infection. Sci Rep, 15(5),7630. doi: 10.1038/srep07630.

Wu, F., Zhao, S., Yu, B., Chen, YM, Wang, W., Song, ZG, Hu, Y., Tao, ZW., Tian, JH., Pei, YY., Yuan, ML., Zhang, YL., Dai, FH., Liu, Y., Wang, QM., Zheng, JJ., Xu, L., Holmes, EC., Zhang, YZ. (2020). A new coronavirus associated with human respiratory disease in China. Nature, 579(7798),265-269. doi: 10.1038/s41586-020-0083-3. Epub 2020 Feb 3.

Xia, S., Zhu, Y., Liu, M., Lan, Q., Xu, W., Wu, Y., Ying, T., Liu, S., Shi, Z., Jiang, S., Lu, L. (2020). Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol, 17(7),765-767. doi: 10.1038/s41423-020-0374-2. Epub 2020 Feb 11.

Xu, J., Zhong, S., Liu, J., Li, L., Li, Y., Wu, X., Li, Z., Deng, P., Zhang, J., Zhong, N., Ding, Y., Jiang, Y. (2005).Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. Clin Infect Dis, 15;41(8),1089-96. Epub 2005 Sep 12.

Xu, X., Chen, P., Wang, J., Feng, J., Zhou, H., Li, X., Zhong, W., Hao, P. (2020). Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci, 63(3),457-460. doi: 10.1007/s11427-020-1637-5.

Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., Zhan, S., Lu, R., Li, H., Tan, W., Liu, D. (2020). In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis, 28;71(15),732-739. doi: 10.1093/ciaa237.

Yeung, ML., Yao, Y., Jia, L., Chan, JF., Chan, KH., Cheung, KF., Chen, H., Poon, VK., Tsang, AK., To, KK., Yu, MK., Teng, JL., Chu, H., Zhou, J., Zhang, Q., Deng, W., Lau, SK., Lau, JY., Woo, PC., Chan, TM., Yung, S., Zheng, BJ., Jin, DY., Mathieson, PW., Qin, C., Yuen, KY. (2016). MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. Nat Microbiol, 22;1:16004. doi: 10.1038/nmicrobiol.2016.4.

Yu, F., Du, L., Ocius, DM., Pan, C., Jiang, S. (2020). Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect, 22(2),74-79. doi: 10.1016/j.micinf.2020.01.003.

Zaki, AM., van Boheemen, S., Bestebroer, TM., Osterhaus, AD., Fouchier, RA. (2012). Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med, 367,1814-20.

Zhang, L., Shen, FM., Chen, F., Lin, Z. (2020).Origin and evolution of the 2019 novel coronavirus. Clin Infect Dis, 28;71(15),882-883. doi: 10.1093/ciaa112.

Zhang, N., Jiang, S., Du, L. (2014). Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines, 13(6),761–74.

Zhang, W., Du, RH., Li, B., Zheng, XS., Yang, XL., Hu, B., Wang, YY., Xiao, GF., Yan, B., Shi, ZL., Zhou, P. (2020). Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect, 17;9(1),386-389. doi: 10.1080/22221751.2020.1729071.

Zhong, NS., Zheng, BJ., Li, YM., Poon, Xie ZH., Chan, KH., Li, PH., Tan, SY., Chang, Q., Xie, JP., Liu, XQ., Xu, J., Li, DX., Yuen, KY., Peiris, Guan Y. (2003). Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s
Republic of China, in February, 2003. *Lancet*, 25;362(9393),1353-8.

Zhou, J., Li, C., Zhao, G., Chu, H., Wang, D., Yan, HH., Poon, VK., Wen, L., Wong, BH., Zhao, X., Chiu, MC., Yang, D., Wang, Y., Au-Yeung, RKH., Chan, IH., Sun, S., Chan, JF., To, KK., Memish, ZA., Corman, VM., Drosten, C., Hung, IF., Zhou, Y., Leung, SY., Yuen, KY. (2017). Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. *Sci Adv*, 15;3(11),eaao4966. doi: 10.1126/sciadv.aao4966. eCollection 2017 Nov.

Zhou, P., Yang, XL., Wang, XG., Hu, B., Zhang, L., Zhang, W., Si, HR., Zhu, Y., Li, B., Huang, CL., Chen, HD., Chen, J., Luo, Y., Guo, H., Jiang, RD., Liu, MQ., Chen, Y., Shen, XR., Wang, X., Zheng, XS., Zhao, K., Chen, QJ., Deng, F., Liu, LL., Yan, B., Zhan, FX., Wang, YY., Xiao, GF., Shi, ZL. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*, 579(7798),270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., Niu, P., Zhan, F., Ma, X., Wang, D., Xu, W., Wu, G., Gao, GF., Tan, W. (2020). China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*, 20;382(8),727-733. doi: 10.1056/NEJMoa2001017.

Zumla, A., Hui, DS., Perlman, S. (2015). Middle East respiratory syndrome. *Lancet*,386,995–1007.